Risk-adapted Therapy for Primary Acute Myeloid Leukemia

NCT04687098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1034

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Idarubicin
DRUG: Ara-C
DRUG: G-CSF
PROCEDURE: Allogeneic matched or unrelated donor transplant.
PROCEDURE: Autologous peripheral blood stem cell transplant
PROCEDURE: Measurable residual disease

Sponsor

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias